Deutsch
TU Dresden

search
Science meets art: PLASMA Release Party at CRTD (June 23)
On June 23, 2017 - we will celebrate the PLASMA Release Party at CRTD. Anyone interested is cordially invited - free entry! [read more]
Panel discussion on Dresdens Science Night: Research discoveries and experiments
Dresden. On 08.06.2017, a press conference for this year's Dresdens Science Night will take place at 1pm at the Gläserne Manufaktur Dresden. The director of the CRTD, Prof. Dr. Ezio Bonifacio, will... [read more]
© CRTD
Professor Michael Sieweke Awarded the Humboldt Professorship at TU Dresden
The selection committee of the Alexander von Humboldt Foundation has followed the nomination of TU Dresden and awarded Professor Michael Sieweke a Humboldt Professorship. One of the most renowned... [read more]
© Jean-Marie Huron
CRTD receives 1.56 Mill. Euro BMBF-funding for retinal disease research
The research groups lead by Prof. Dr. Elly Tanaka, Prof. Dr. Marius Ader and Dr. Mike Karl at the CRTD have received funding with their CLEANSIGHT research team.  [read more]
© CLEANSIGHT


At the DFG-Center for Regenerative Therapies Dresden (CRTD), our mission is to understand the biology of stem cells and physiological and pathological tissue and organ repair in order to develop new treatments for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, haematological diseases, such as leukemia, metabolic diseases, such as diabetes, and bone diseases. Our scientists are encouraged to think outside the box and to explore untapped areas of knowledge in the regenerative potential of the human body, and to apply this knowledge to prevent or reverse disease processes.

To achieve our aims, we strongly support interdisciplinary research, with eighteen core groups in a network of 87 principal investigators from diverse research institutes on the Dresden campus, with expertise in everything from the biology of cells and tissues to biomaterials to nanoengineering. CRTD has become a major driving force on campus and is ready to meet the challenges of moving new interventional strategies from bench to bedside.